Compare IMVT & THO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMVT | THO |
|---|---|---|
| Founded | 2018 | 1980 |
| Country | United States | United States |
| Employees | 362 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Homebuilding |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.3B |
| IPO Year | 2019 | 1994 |
| Metric | IMVT | THO |
|---|---|---|
| Price | $26.46 | $86.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $30.78 | ★ $112.75 |
| AVG Volume (30 Days) | ★ 1.2M | 620.6K |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | ★ 2.30% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $9,579,490,000.00 |
| Revenue This Year | N/A | $1.62 |
| Revenue Next Year | N/A | $5.21 |
| P/E Ratio | ★ N/A | $120.35 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.72 | $63.16 |
| 52 Week High | $29.25 | $122.83 |
| Indicator | IMVT | THO |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 19.11 |
| Support Level | $24.63 | $84.57 |
| Resistance Level | $27.71 | $110.73 |
| Average True Range (ATR) | 1.07 | 3.89 |
| MACD | -0.05 | -2.60 |
| Stochastic Oscillator | 26.02 | 1.57 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Based in Elkhart, Indiana, Thor Industries manufactures Class A, Class B, and Class C motor homes along with travel trailers and fifth-wheel towables across about 35 brands. Through the acquisition of Erwin Hymer in 2019, the company expanded its geographic footprint and now produces various motorized and towable recreational vehicles for Europe, including motor caravans, camper vans, urban vehicles, caravans, and other RV-related products and services. The company has also begun generating revenue through aftermarket component parts via the acquisition of Airxcel in 2021; however, this is still a nascent part of the business as it accounts for less than 10% of fiscal 2025 total sales. In fiscal 2025, the company wholesaled 181,388 units and generated $9.6 billion in revenue.